Business context and reporting period
This is Foresight Acquisition Corp.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021—not a standalone P3 Health Partners filing. Foresight was a blank-check company and had no operating revenue or business operations before a business combination. It signed a proposed merger with P3 Health Group Holdings, LLC on May 25, 2021; the transaction had not closed by quarter-end.
Financial results and liquidity
- Revenue and margins: No operating revenue; margins are not meaningful for this pre-combination SPAC.
- Net loss: $10.5 million for Q2 and $5.7 million for the first six months of 2021. Q2 included $9.9 million of noncash warrant fair-value expense; the six-month period included $4.6 million.
- Operating costs: General and administrative expenses were $639,534 for Q2 and $1.12 million for the six months. Interest income was $10,449 for each period.
- Cash flow: Six-month operating cash use was $953,782. IPO and private-placement proceeds funded $316.25 million placed in the trust account; cash outside the trust was $583,701 at June 30.
- Assets and liabilities: Total assets were $317.1 million, including $316.3 million in the trust account. Total liabilities were $15.9 million, primarily $15.7 million of warrant liabilities. No long-term debt was reported.
- Liquidity: Foresight also disclosed a sponsor commitment for $300,000 in loans on August 19, 2021. Trust funds were principally reserved for a business combination and were not ordinary operating liquidity.
Material changes versus the prior comparable period
The filing does not provide prior-year quarterly operating results for comparison; Foresight began its IPO in February 2021 and had no operations. Compared with December 31, 2020, cash rose to $583,701 from $179,512 and the trust account held $316.3 million; warrant liabilities were newly recorded at $15.7 million. The warrant accounting change drove substantial reported earnings volatility and is not an operating cash expense.
Transaction, outlook, risks and unusual items
- Proposed P3 transaction: The stated aggregate merger consideration was $2.126 billion. Assuming no public-share redemptions and $208.7 million of PIPE proceeds, consideration was expected to include $181.1 million of P3 units and $315.0 million cash, subject to adjustment if post-transaction cash falls below $180 million. A separate merger closing condition required at least $400 million of aggregate cash after specified adjustments, including redemptions and expenses. Completion remained subject to approvals and other conditions.
- PIPE: Investors agreed to purchase 20,870,307 Foresight Class A shares at $10 each, contingent on the transaction closing.
- Deadline and contingency: Foresight was required to complete a business combination by February 12, 2023, subject to possible extension; otherwise, it generally must liquidate and redeem public shares, while warrants may expire worthless.
- Accounting and controls: Following SEC staff guidance, Foresight classified its warrants as liabilities and remeasured them at fair value. Management reported a material weakness in internal control over financial reporting related to the warrant restatement; disclosure controls were therefore not effective as of June 30. Remediation was ongoing.
- Other risks and costs: Management said the COVID-19 impact on the company or its search was not readily determinable. The company reported no legal proceedings. It also expected to pay underwriters a 3.5% fee on IPO gross proceeds upon a completed business combination.
Important facts for investors to verify
- Whether the P3 transaction closed, and the final redemptions, PIPE funding, cash condition and consideration mix.
- Progress in remediating the material weakness and whether subsequent filings report further accounting or control issues.
- Future warrant fair-value changes, which may materially affect reported earnings without corresponding operating cash flows.
- Available cash outside the trust, sponsor-loan terms and any additional financing needed to complete the transaction or fund operations.
- The business-combination deadline or any extension, and the consequences for public shares and warrants if no transaction is completed.